Changes in Hong Kong stocks | Yingen Bio-B (09606) rose more than 12% in 2026, Catalyst Enrichment Agency raised the company's target price

The Zhitong Finance App learned that Yingen Bio-B (09606) rose by more than 12%. As of press release, it had risen 12.08% to HK$332.2, with a turnover of HK$321 million.

According to the news, Cathay Pacific Haitong Securities pointed out that according to the summary, Yingen Biotech is rich in catalysts in 2026. The bank is looking forward to reading the following data: 1) the final results of HER2 ADC for EC and BC indications; 2) clinical results of B7H3 ADC, HER2 ADC, and TROP2 ADC combined with PDL1*VEGF dual anti-BNT327; 3) Early clinical data updates for B7H4 ADC, EGFR*HER3 ADC in the BD pipeline, and clinical progress of CDH17 ADC Update; 4) FIH data disclosure for early pipeline PDL1*B7H3 ADC.

The bank said that based on the extremely smooth progress of Yingen Biotech's pipeline in 2025, it raised expectations for potential peak global sales of HER2 ADCDB1303, B7H3 ADCDB1311, and HER3 ADCDB1310. Using the DCF valuation method, the bank raised the target price of Yingen Biotech to HK$455.56, maintaining an increase in holdings rating.